论文部分内容阅读
目的探讨放射性核素骨显像和血清前列腺特异抗原(PSA),碱性磷酸酶(ALP),骨特异性碱性磷酸酶(BAP)测定在前列腺癌骨转移诊断中的价值。方法回顾性分析2006年10月-2009年10月50例前列腺癌(PCa)患者骨显像结果及PSA、ALP、BAP测定结果。结果 50例Pca患者骨显像阳性率为70.0%。35例Pca骨转移患者分布在PSA>20.0ng/mL时占97.1%,BAP>20.1μg/L时占88.6%,ALP>130.0μg/L时占94.3%。血清PSA、ALP、BAP水平随着放射性核素骨显像分级的增高而逐步增高,呈高度正相关。结论放射性核素骨显像仍然是目前诊断PCa骨转移的主要方法;PSA、ALP、BAP亦是重要的辅助诊断指标;PSA>20.0ng/mL时,患者应常规行全身骨显像检查。
Objective To investigate the value of radionuclide bone imaging and serum prostate specific antigen (PSA), alkaline phosphatase (ALP) and bone specific alkaline phosphatase (BAP) in the diagnosis of bone metastasis of prostate cancer. Methods The results of bone imaging and PSA, ALP and BAP in 50 patients with prostate cancer (PCa) from October 2006 to October 2009 were retrospectively analyzed. Results The positive rate of bone imaging in 50 cases of Pca was 70.0%. The distribution of 35 patients with Pca bone metastasis was 97.1% with PSA> 20.0ng / mL, 88.6% with BAP> 20.1μg / L and 94.3% with ALP> 130.0μg / L. Serum PSA, ALP, BAP levels gradually increased with the increase of radionuclide bone imaging grading, showing a highly positive correlation. Conclusions Radionuclide bone imaging is still the main method for the diagnosis of PCa bone metastasis. PSA, ALP and BAP are also important auxiliary diagnostic indicators. When PSA> 20.0ng / mL, patients should undergo routine bone scintigraphy.